Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(14%)
Results Posted
100%(4 trials)

Phase Distribution

Ph phase_4
1
14%
Ph phase_3
3
43%
Ph phase_1
3
43%

Phase Distribution

3

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Withdrawn1
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (42.9%)
Phase 33 (42.9%)
Phase 41 (14.3%)

Trials by Status

completed457%
withdrawn114%
recruiting114%
not_yet_recruiting114%

Recent Activity

1 active trials
Showing 5 of 7
recruitingphase_3

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

NCT05784246
not_yet_recruitingphase_4

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

NCT07292012
completedphase_3

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03524092
completedphase_1

A Safety Study of Mirikizumab (LY3074828)

NCT01947933
completedphase_1

A Study of Mirikizumab (LY3074828) in Healthy Participants

NCT02568423
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05784246Phase 3

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
NCT07292012Phase 4

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

Not Yet Recruiting
NCT03524092Phase 3

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Completed
NCT01947933Phase 1

A Safety Study of Mirikizumab (LY3074828)

Completed
NCT02568423Phase 1

A Study of Mirikizumab (LY3074828) in Healthy Participants

Completed
NCT04137380Phase 1

A Study of Mirikizumab in Healthy Chinese Participants

Completed
NCT04469062Phase 3

A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7